



ABN 53 075 582 740

ASX ANNOUNCEMENT

21 July 2020

RESTATEMENT OF ACCOUNTS – NO IMPACT ON CASH POSITION OR BUSINESS STRATEGY

Bionomics Limited (ASX: BNO, OTCQB:BNOEF), a global, clinical stage biopharmaceutical company announced today that, following the amendment to the US Bank Loan facility that occurred during May 2020 to defer principal repayment until November 2020 and extend final maturity until 1 January 2022, Bionomics' management became aware that the final loan payment, under the original loan facility, had not been accounted for appropriately resulting in an understatement of non-current bank borrowings. The omission is the failure to accrue for this liability and there is no impact on the current cash position or the fundraising strategy to advance the tablet formulation of BNC210 to Phase 2 clinical trials for the treatment of post-traumatic stress disorder.

This has resulted in an increase in non-current borrowings and a decrease in net assets reported in the Consolidated Statement of Financial Position as at 30 June 2018, 30 June 2019 and 31 December 2019 by \$507,000, \$1,199,000, and \$1,489,000 respectively.

The loss after tax reported in the Consolidated Statement of Profit or Loss and Other Comprehensive Income has therefore increased for the years ending 30 June 2018 and 2019, and half-year ended 31 December 2019 by \$507,000, \$692,000 and \$290,000, respectively.

After due consideration, the Board is of the view that it is preferable to restate the affected comparative financial information, which will appear in the Company's FY2020 Financial Statements in due course.

AUTHORISED BY THE BOARD

FOR FURTHER INFORMATION PLEASE CONTACT:

Mr Adrian Hinton
Acting CFO
+61 8 8354 6181
ahinton@bionomics.com.au

About Bionomics Limited

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of agitation, is a novel, proprietary negative allosteric modulator of the alpha-7 ($\alpha 7$) nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) and a pipeline of pre-clinical ion channel programs targeting pain, depression, cognition and epilepsy.

www.bionomics.com.au